▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2844 by analyst upside · 2026-08-13
BIIB
Biogen Inc.
Healthcare · Market Cap $31B · P/E 37.1x
ANALYST PRICE TARGET
+12.8%
implied upside to consensus target
Current Price $208.87
Consensus Target $235.57
Bull Target $300.0
Bear Target $165.0
Analysts Covering 31
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
17
Hold
10
Sell
1
52-Week Low $129.4
52-Week High $219.72
YTD Return +17.5%
FUNDAMENTALS
Market Cap $31B
P/E Ratio (TTM) 37.1x
Forward P/E 12.6x
EPS (TTM) $5.63
PEG Ratio 4.99
Dividend Yield N/A
Revenue (TTM) $10.0B
Profit Margin 8.3%
52-WEEK RANGE
52-Week Low $129.4
52-Week High $219.72
Current Price $208.87
Bear Target $165.0
Bull Target $300.0
● Now $208.87 ● Target $235.57
TRADING DATA
Avg Volume 1.2M
YTD Return +17.5%
Analyst Count 31
Consensus Buy
Upside to Target +12.8%
Last Updated 2026-08-13

ANALYST SUMMARY

Biogen Inc. (BIIB) is currently trading at $208.87 with a Wall Street consensus price target of $235.57, implying potential upside of 12.8% over the next 12 months. 31 analysts currently cover BIIB, with a consensus rating of Buy - 65% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $300.0, while the most cautious has a target of $165.0.

BIIB operates in the Healthcare sector with a market capitalisation of $31B. The stock is up 17.5% year-to-date and is currently trading near the upper end of its 52-week range of $129.4 – $219.72.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

MTD +2.1%
Mettler-Toledo International, I
$29B · P/E 32.4x · Buy
IDXX +22.5%
IDEXX Laboratories, Inc.
$45B · P/E 40.0x · Buy
WST +14.9%
West Pharmaceutical Services, Inc.
$25B · P/E 45.2x · Buy
ILMN +2.7%
Illumina, Inc.
$29B · P/E 36.0x · Buy
ZTS +37.3%
Zoetis Inc.
$30B · P/E 12.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for BIIB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-06-18 Building track record
Mizuho - Reiterated
Outperform → Outperform 2026-06-15 Building track record
Needham ↑ Upgrade
Hold → Buy 2026-06-08 20% win rate (5 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-05-27 Building track record
Piper Sandler reit
Overweight → Overweight 2026-05-15 14% win rate (7 calls)
Citigroup - Reiterated
Neutral → Neutral 2026-05-01 Building track record
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-04-30 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-04-30 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
57
out of 100
Coverage depth
26/30
Consensus clarity
17/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →